Oxford Gene Technology (OGT) has announced a strategic realignment of its commercial operations to fuel further growth in its high-value genomics products portfolio. As part of this realignment, OGT will transfer its next-generation sequencing services business to Source BioScience.
Mike Evans, OGT chief executive, commented, “Our strategic focus on the large and growing genomic medicine markets of cancer, molecular cytogenetics and reproductive health has delivered significant commercial growth. OGT’s genomics products portfolio has been growing over the last four years and we have thus aligned our strategy and resources behind our genomics product business.”
OGT’s high-growth, product-focused strategy has been exemplified through the acquisition of Cytocell, a leading provider of fluorescence in situ hybridisation (FISH) probes, in 2014, and its subsequent successful integration. OGT now has a strong, rapidly growing core business comprised of CytoSure arrays and Cytocell FISH probes, with further product growth opportunities from its recently launched SureSeq range of cancer panels and its CytoSure Affirm non-invasive prenatal test (NIPT) currently in clinical trials.
Mike Evans continued: “We will be providing our genetics analysis service customers with a high-calibre alternative to OGT. We have worked closely with Source BioScience, to ensure customers will continue to receive best-in-class service and support, coupled with a seamless transition. Furthermore, OGT’s analysis software will be licensed to Source BioScience as part of the transfer, allowing customers continued access to the consistent, high-quality genetic analysis that OGT provides.”
www.ogt.com